OKYO Pharma Limited (OKYO)
$1.9856
+0.02 (+0.79%)
Rating:
Recommendation:
-
| Symbol | OKYO |
|---|---|
| Price | $1.9856 |
| Beta | -2.859 |
| Volume Avg. | 0.26M |
| Market Cap | 56.033M |
| Shares () | - |
| 52 Week Range | 0.92-7.0 |
| 1y Target Est | - |
| DCF Unlevered | OKYO DCF -> | |
|---|---|---|
| DCF Levered | OKYO LDCF -> | |
| ROE | 999.45% | Strong Buy |
| ROA | -59.59% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | -107.88% | Sell |
| P/E | -3.15 | Strong Sell |
| P/B | -14.57 | Strong Sell |
Latest OKYO news
About
Download (Excel)OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.